Foot Locker Stock a...
Health Care: Drugs
Theravance Inc. (THRX: NASDAQ)
$35.60 -0.11 | -0.31%
06/19/13 - 10:10 AM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 35.71 |
| 52 Week High | 42.41 |
| 52 Week Low | 19.61 |
| Avg. Daily Vol. (Mil) | 1.65 |
| Beta (3 year) | 1.72 |
| Share Related Items | |
| Mkt Cap (Mil) | 3,551.49 |
| Shares Out (Mil) | 99.45 |
| Float (Mil) | 41.13 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 15.00 |
| Current Ratio | 16.10 |
| LT Debt/ Equity | 5.03 |
| Total Debt / Equity | 5.03 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 355.08 |
| Price/Book | 38.81 |
| Price/Cash Flow | -26.70 |
| Per Share Data | |
| Earnings | -1.52 |
| Sales | 0.10 |
| Book Value | 0.92 |
| Cash Flow | -1.34 |
| Business Summary | |
|---|---|
| Theravance Inc., is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical. | |
| General Information | |
| 901 Gateway Boulevard
South San Francisc, CA 94080 |
|
| www.theravance.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 226 | |
| CEO: Rick E. Winningham | |
| Short Interest | |
| Current Month (Mil) | 11.52 |
| Previous Month (Mil) | 12.62 |
| Short Interest Ratio (Days) | 6.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -23.80 |
| Return on Investments | -25.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with THRX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorEarnings Short Squeeze Play...
- ProSeth Klarman - Baupost Group
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Usernew
Latest THRX Headlines from TheStreet
- Elan Shareholder Vote Nixes Royalty Pharma Takeover -- For Now 06.17.13 | 07:06 am
- Commit To Purchase Theravance At $25, Earn 13.2% 06.14.13 | 12:06 pm
- Theravance Inc. (THRX): Today's Featured Drugs Laggard 06.13.13 | 05:06 pm
- Stocks Finish Flat as Earnings Wind Down 05.13.13 | 11:05 am
- Stock Futures Lower Ahead of Retail Sales 05.13.13 | 06:05 am
- 4 Stocks Spiking on Big Volume 05.10.13 | 03:05 pm
- Buffett's Long-Term, High-Dividend Plays 05.04.13 | 03:05 am
- Theravance Inc. (THRX): Today's Featured Health Care Laggard 04.19.13 | 05:04 pm
- 3 Stocks Pushing The Drugs Industry Higher 04.15.13 | 01:04 pm
- 5 Stocks Poised to Pop on Bullish Earnings 02.11.13 | 12:02 pm
Press Releases for THRX
- BREOâ¿¢ ELLIPTAâ¿¢ Gains US Approval For The Treatment Of COPD - PR Newswire 05.10.13 | 04:05 pm
- FDA Advisory Committee Recommends Approval Of BREOâ¿¢ ELLIPTAâ¿¢ For The Treatment Of COPD - PR Newswire 04.17.13 | 05:04 pm
Partner Headlines for THRX
- Elan / Royalty Pharma: number crunchers - Financial Times 05.31.13 | 12:05 am
- Elan Rejects Royalty Offer Again - Analyst Blog - Zacks 05.24.13 | 10:05 pm
- Elan steps up fight against Royalty Pharma bid - Financial Times 05.20.13 | 05:05 pm
- Theravance, Glaxo, Elan Star In Biotech Soap Opera - Investor's Business Daily 05.13.13 | 05:05 pm
- Glaxo, Theravance Confirm BREO ELLIPTA Gained US FDA Approval for Treatment of COPD - Benzinga 05.10.13 | 12:05 pm
- Theravance Earnings: Here’s Why Investors Don’t Like These Results - Wall St. Cheat Sheet 04.25.13 | 08:04 am
- Morning Market Movers - Benzinga 04.15.13 | 09:04 am
- Pipeline Progress at Theravance - Analyst Blog - Zacks 12.05.12 | 09:12 am
- Glaxo Invests in Nigeria - Analyst Blog - Zacks 11.28.12 | 09:11 am
- For NovaBay, Simplicity Is The Father Of Invention - Seeking Alpha 11.12.12 | 09:11 am
